NASDAQ:CALC CalciMedica Q4 2025 Earnings Report $0.80 +0.04 (+5.75%) As of 02:09 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast CalciMedica EPS ResultsActual EPS-$0.69Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACalciMedica Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACalciMedica Announcement DetailsQuarterQ4 2025Date3/3/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsCalciMedica's next earnings date is estimated for Tuesday, August 11, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile CalciMedica Earnings HeadlinesCalciMedica, Inc.: CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational EndpointsJuly 29, 2026 | finanznachrichten.deCalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational EndpointsJuly 29, 2026 | prnewswire.comApple just sent a powerful signal to investorsApple just crossed a $5 trillion market value as shares climbed 25% this year, fueled by new product launches and rising interest in foldable phones. Mode Mobile is building on top of that ecosystem with its EarnOS platform, already serving 490M+ users across 170+ countries and generating $115M+ in lifetime revenue. Deloitte ranked Mode North America's number 1 fastest-growing software company in 2023 after 32,481% growth. Pre-IPO shares are available at $0.52 before the price changes on August 14.August 4 at 1:00 AM | Mode Mobile (Ad)CalciMedica, Inc.: CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety DataJune 25, 2026 | finanznachrichten.deAnalysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and CalciMedica (CALC)June 25, 2026 | theglobeandmail.comCalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension ProgramJune 24, 2026 | prnewswire.comSee More CalciMedica Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email. Email Address About CalciMedicaCalciMedica (NASDAQ:CALC), Inc. (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses. The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia. Early-phase data suggest that CRAC channel inhibition can reduce inflammatory cytokine release and support organ function in critically ill patients. CalciMedica pursues a development strategy that combines rigorous clinical evaluation with strategic collaborations to expedite potential regulatory approvals and commercialization. Operating primarily in the United States, the company works closely with academic centers and healthcare organizations to advance its pipeline. By targeting calcium signaling in innate immune cells, CalciMedica aims to fill unmet medical needs in acute inflammatory diseases and improve outcomes for high-risk patient populations.View CalciMedica ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The AI Chip Stock Making a Quiet Move Toward DominanceApple’s AI Strategy Looks Different—Will It Pay Off?Reddit’s U.S. User Decline Raises a Bigger Question After Its Earnings BeatWhy Walmart and Amazon Could Be the Market’s Most Complementary Mega-CapsMarriott’s Earnings Drop May Be Missing the Bigger Fee Growth StoryDodging Deutsche Telekom: T-Mobile's Strategic WinSpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control Upcoming Earnings DoorDash (8/5/2026)Walt Disney (8/5/2026)MercadoLibre (8/5/2026)Occidental Petroleum (8/5/2026)Phillips 66 (8/5/2026)Allstate (8/5/2026)Brookfield Asset Management (8/5/2026)MetLife (8/5/2026)Manulife Financial (8/5/2026)Block (8/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
